RIPE-KG · Version 1.1.0 · Resource
ripekg:publication-details/RIPEA44B073B6366CEDA7
https://w3id.org/ripe/ripe-kg/publication-details/RIPEA44B073B6366CEDA7
| Subject | Predicate | Object |
|---|---|---|
ripekg:evaluation/RIPEA44B073B6366CEDA7 |
prov:used |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prism:eIssn |
1365-2869 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prism:issn |
0962-1105 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prism:publicationDate |
2024-10-08 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prism:publicationName |
Journal of Sleep Research |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
dcterms:publisher |
ripekg:publisher/RIPEP932ECA8E36309A4DWiley |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
dcterms:title |
Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
http://purl.org/spar/fabio/BibliographicMetadata |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
rdfs:Resource |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
owl:Thing |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
ripe:PublicationDetailsPublication details |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
rdf:type |
tido:Evidence |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA44B073B6366CEDA7 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripe:concerns |
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-human-1-1 |
ripekg:publication-details/RIPEA44B073B6366CEDA7Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-inspectai-1-1 |